IXICO Announces Appointment of Chief Financial Officer
IXICO plc has announced that Susan Lowther FCMA has been appointed to the board as Chief Financial Officer with effect from 1 October 2014.
Prior to her recent appointment at IXICO Susan was Chief Financial Officer and a director of Lab21 Group Limited. Lab21 was acquired by Novacyt in June 2014 by way of a share for share transaction, valuing the enlarged group at circa €40 million. Susan was previously Chief Financial Officer at BioWisdom Limited and has held finance roles in life science companies including RiboTargets, Lonza Biologics, Celltech Group and Monsanto.
Commenting on the appointment Derek Hill, CEO of IXICO, said:
"We are delighted that Susan is joining the IXICO team. She brings a depth of financial and business experience that will help us continue to grow the business internationally."
For more information and to view the full press release please download the attached PDF.